

DT07 Rec'd PCT/PTO 0 4 MAR 2005

CASE 4-32444A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<u>EV52461502045</u> Express Mail Label Number	<u>3/4/05</u> Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

COPPOLA ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP 03/03466

FILED: 2 APRIL 2003

U.S. APPLICATION NO: 10/510,026

35 USC §371 DATE: ~~10/5/03~~

FOR: 5-SUBSTITUTED 1,1-DIOXO-1,2,5-THIADIAZOLIDIN-3-ONE
DERIVATIVES

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The asterisked references were cited in the International Search Report and since copies of said references were forwarded by the International Bureau, only copies of the non-asterisked references are enclosed.

The PTO did not receive the following
listed items(s) For and NPL

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Paivi Kukkola
Agent for Applicants
Reg. No. 50,499

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7875

Date: March 4, 2005

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-32444A
APPLICATION NO.
10/510,026
APPLICANT
COPPOLA ET AL.
FILING DATE
OCTOBER 1, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,958,957	9/28/99	Anderson et al.	514	364	4/16/97
	AB	5,972,978	10/26/99	Anderson et al.	514	361	2/19/99
	AC	6,063,800	5/16/00	Anderson et al.	514	369	2/19/99
	AD	6,080,770	6/27/00	Anderson et al.	514	359	2/19/99
	AE	5,162,340	11/10/92	Chakravarty et al.	514	309	5/10/91
	AF	5,281,614	1/25/94	Ashton et al.	514	359	11/2/92
	AG	5,412,097	5/2/95	Chakravarty et al.	546	118	9/2/92
	AH	5,972,978	10/26/99	Andersen et al.	514	361	2/19/99
	AI						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
*	AJ	WO 97/40017	10/30/97	PCT			<input type="checkbox"/>	<input type="checkbox"/>
*	AK	WO 01/19831	3/22/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AL	0 512 870	11/11/92	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AM	WO 92/20687	11/26/92	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AO	Albericio et al., "Synthesis of a Sulfahydantoin Library", J. Comb. Chem. Vol. 3, pp 290-300 (2001)
*	AP	Bright et al., "Competitive particle concentration fluorescence immunoassays for measuring antidiabetic drug levels in mouse plasma" Journal of Immunological Methods, vol. 207, pages 23-31(1997),
	AQ	Abstract, Eberle et al., "Preparation of microbiocidal N-phenyl-N [4- (-pyridyl)-pyrimidin-2-yl] amines
	AR	Ducry et al., "Synthesis of 1,2,5-Thiadiazolidin-3-one 1,1-Dioxide Derivatives and evaluation of their affinity for MHC Class-II Proteins", Helvetica Chimica, Acta, Vol. 82, No. 12, pp. 2432-2447 (1999)
*	AS	Mantegani et al., "Synthesis and Antihypertensive Activity of 2,4-dioxoimidazolidin-1-yl and perhydro-2,4-dioxypyrimidin-1-yl ergoline derivatives", IL FARMACO, vol. 53, pp 293-304 (1998)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.